The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Exercise of Warrants

7 Mar 2018 12:29

RNS Number : 9943G
Motif Bio PLC
07 March 2018
 

Exercise of Warrants

 

Motif Bio plc (AIM/NASDAQ: MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced that it has received notification from a warrant holder to exercise warrants representing 178,571 ordinary shares of 1p each ("Ordinary Shares") in the Company at an exercise price of 32.2p per warrant for total consideration of £57,499.86.

 

Application has been made for the 178,571 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 13 March 2018. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Following Admission, and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 264,276,443 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.

 

For further information, please contact:

 

Motif Bio plc

info@motifbio.com

Graham Lumsden (Chief Executive Officer)

 

 

 

 

Peel Hunt LLP (NOMAD & BROKER)

 

+ 44 (0)20 7418 8900

Dr Christopher Golden

 

Oliver Jackson

 

 

 

 

Northland Capital Partners Limited (BROKER)

 

+44 (0)203 861 6625

David Hignell/John Howes/Rob Rees

 

 

 

 

 

 

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

 

+44 (0) 20 7933 8780 / motifbio@walbrookpr.com

Paul McManus/Helen Cresswell/Lianne Cawthorne

 

 

 

 

MC Services AG (EUROPEAN IR)

 

+49 (0)89 210 2280

Raimund Gabriel

raimund.gabriel@mc-services.eu

The Trout Group (US IR)

+1 (646 )378-2963

Meggie Purcell

mpurcell@troutgroup.com

Russo Partners (US PR)

+1 (858) 717-2310 +1 (212)845-4272

David Schull

david.schull@russopartnersllc.com

Travis Kruse, Ph.D.

travis.kruse@russopartnersllc.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSSIFEWFASEED
Date   Source Headline
22nd Jul 20154:32 pmRNSFDA QIDP Designation
22nd Jul 20157:00 amRNSFinal condition of £22m placing satisfied
20th Jul 20157:00 amRNSExercise of Options
17th Jul 20157:00 amRNSFDA QIDP Designation for Iclaprim for HABP
15th Jul 20157:00 amRNSNew Addition to Scientific Advisory Board
10th Jul 20153:29 pmRNSExercise of Options
10th Jul 20151:37 pmRNSResult of General Meeting
23rd Jun 20158:47 amRNSPartner Company raises £22 million
23rd Jun 20157:00 amRNSPlacing to raise £22 million and Change of Adviser
9th Jun 20157:00 amRNSAudited Non-Statutory Financial Statements
4th Jun 20154:41 pmRNSSecond Price Monitoring Extn
4th Jun 20154:35 pmRNSPrice Monitoring Extension
1st Jun 20157:00 amRNSMotif partners with Leading Global CRO
28th May 20157:00 amRNSFDA Meeting Minutes Confirming Iclaprim Phase III
12th May 20157:01 amRNSMOTIF SELECTED TO PRESENT AT BIOTECH EVENT
7th May 20157:00 amRNSFunding Strategy Update
15th Apr 20157:01 amRNSFDA Results
15th Apr 20157:00 amRNSFDA agree to enter clinical development programme
2nd Apr 20157:00 amRNSFirst Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.